About this trial
This study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (DCB) angioplasty for below the knee arterial lesions in patients critical with Limb Threatening Ischemia (CLTI).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Rutherford grade 4-6.
Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up.
Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries >20 mm. Lesions should not extend beyond the ankle joint.
Successful wire crossing of the lesion. After the pre-dilation of the ordinary balloon, the angiography showed that there was continuous blood flow.
Disqualifiers
Blood flow was not successfully reestablished.
Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.
Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.
Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.
Trial population
Patients suffered with Chronic Limb Theratening Ischemia and with significant infrapopliteal artery lesions.
Trial design
Cohort
Other
Treatments tested in this trial
drug-coated balloon
DeviceTo evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.
Treatment groups
Trial outcomes
Primary outcomes
Primary sustained clinical improvement at 12 months post-procedure
Primary sustained clinical improvement was defined as an upward shift on the Rutherford classification (Appendix) to a level of intermittent claudication without the need for repeated TLR in surviving patients without the need for unplanned amputation.
Freedom of major limb adverse events at 12 months post-procedure
Major limb adverse events were defined as the composite of clinically-driven target lesion revascularization (CD-TLR); unplanned, unavoidable major amputation of the index limb; and treatment caused death.
Secondary outcomes
Patency of the target lesions at 1 month, 3 months, 6 months and 12 months post-interventional
Patency includes the absence of clinically driven target lesion revascularization and/or recurrent target lesion diameter stenosis ≥50% by imaging (e.g., invasive angiography or, most commonly, duplex ultrasonography).
Procedural success rate
Procedural success for peripheral revascularization is defined as both technical success and absence of major adverse events (e.g., death, stroke, myocardial infarction, acute onset of limb ischemia, index bypass graft or treated segment thrombosis, and/or need for urgent/emergent vascular surgery) within 72 hours of the index procedure.
Vascular quality of life questionnaire(VascuQol)
The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life. 1 month, 3 months, 6 months, 12 months
Wound healing rate
Wound healing in patients with Rutherford grade 5.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Lead sponsor
Xuanwu Hospital, Beijing
Collaborator
RenJi Hospital
Collaborator
Zhejiang University
Collaborator
First People's Hospital of Hangzhou
Collaborator
Second Affiliated Hospital of Suzhou University
Collaborator
Qingdao University
Collaborator
Chengdu University of Traditional Chinese Medicine
Collaborator
Shanghai Zhongshan Hospital
Collaborator
Huashan Hospital
Collaborator